Introduction {#S1}
============

Stem cell therapy has garnered much attention and application in the past decades for the treatment of diseases and injuries. Among the different stem cell types, mesenchymal stem cells (MSCs) are studied most extensively, particularly for their application in regenerative medicine and tissue engineering ([@B11]). MSCs are being widely researched for their therapeutic roles. MSCs are multipotent stromal cells that can differentiate into a variety of cell types ([@B80]) and can be obtained from four common sources: adipose tissue, peripheral blood, bone marrow, and umbilical cord/blood ([@B26]; [@B78]; [@B72]). Initially, the therapeutic efficiency of MSCs was attributed to their ability to migrate and engraft in target tissues; however, studies show that systemically administered MSCs rarely reach the target in great numbers ([@B25]), suggesting that the biological effects observed due to stem cell administration are likely due to their secreted factors. These secreted factors are attributed to several beneficial effects, such as neuroprotection, neurogenesis, myocardial protection, inflammation, etc ([@B44]; [@B92]; [@B32]).

Recent studies on extracellular vesicles (EV) and their function have shed light on their crucial role in mediating cell-to-cell communication ([@B93]). EV are nano-sized membrane-bound vesicles (size range 30--1000 nm) that shuttle important biomolecules between cells ([@B82]; [@B55]; [@B76]), maintain physiological homeostasis ([@B98]), and influence pathogenesis ([@B81]). Studies show that EV from MSCs (MSC-EV) have regenerative and anti-inflammatory properties in animal models of stroke ([@B22]; [@B7]; [@B20]), traumatic brain injury ([@B37]; [@B21]; [@B63]), wound healing ([@B97]), and perinatal brain injury ([@B77]). Recent studies demonstrated that MSC-EV exert biological effects comparable to those of the parent cells ([@B12]; [@B44]; [@B61]; [@B73]; [@B5]) and mediate the paracrine effects of the MSCs ([@B15]; [@B90]). While there are only a few studies that directly compare MSC-EV treatments to MSCs treatments, the overlapping effects seem to indicate that MSCs are merely the vehicle and that MSC-EV have a greater likelihood of impacting damaged areas ([@B58]). The use of MSC-EV, as an alternative to MSCs, confers several advantages such as higher safety profile ([@B95]), lower immunogenicity ([@B60]), and the ability to cross biological barriers ([@B102]). Additionally, use of MSC-EV avoids complications that arise from stem cell-induced ectopic tumor formation, entrapment in lung microvasculature, and immune rejection ([@B4]; [@B33]; [@B85]; [@B24]). These advantages and the growing evidence of MSC-EV having therapeutic roles contribute to the strong rationale, if not the necessity, for developing EV as therapeutic treatment options.

Preclinical Studies of Msc-Ev {#S2}
=============================

The therapeutic efficiency of human MSC-EV has been tested in preclinical animal models and across many diseases and injuries. [@B50] showed that human umbilical cord MSC (hUCMSC)-derived exosomes (that are extracellular vesicles of 30--150 nm range) could ameliorate the carbon tetrachloride-induced liver fibrosis by providing hepatic protection and inhibiting the detrimental epithelial-to-mesenchymal transition. Further, hUCMSC-derived EV are shown to ameliorate experimental autoimmune uveoretinitis by inhibiting inflammatory cell migration ([@B6]). Exosomes from hUCMSCs are also suggested as therapeutic tools for cisplatin-induced nephrotoxicity ([@B101]). [@B9] demonstrated that hUCMSC-derived EV protect cardiac tissue from ischemic injury, partly by promoting angiogenesis, in a rat model of myocardial infarction. In atopic dermatitis mouse models, intravenous administration of EV from human adipose tissue-derived MSCs (hAMSCs) has shown anti-atopic effects ([@B17]). EV from hAMSCs are also shown to possess therapeutic potential in neurodegenerative disorders, such as Alzheimer's disease (AD), and Huntington's disease. In an *in vitro* AD mouse model, hAMSC-derived EV are shown to ameliorate the progression of beta-amyloid-induced neuronal death ([@B45]). Investigation of the therapeutic effects of hAMSC-derived exosomes in *in vitro* Huntington's model revealed their neuroprotective effects; the Huntington's disease phenotype was ameliorated via modulation of mutant Huntington aggregates' mitochondrial and apoptotic functions ([@B46]). Interestingly, this neuroprotective property seems to influence the neurodevelopment of the fetal brain; it has been shown that application of human bone marrow (hBMMSC)-derived EV is capable of protecting the development of fetal brains afflicted with hypoxia ([@B67]). As highlighted in [Figure 1](#F1){ref-type="fig"}, several preclinical studies showed success in applying MSC-EV; however, generating success in the lab is not enough to generate conclusive clinical results.

![Therapeutic roles of human MSC-derived EV in various diseases. MSC-EV from different sources (hUCMSCs, hBMSCs, hATMSCs) are shown to ameliorate disease conditions such as Alzheimer's (AD), Parkinson's (PD), and cirrhosis. It also effects cell and organ injuries such as microbial ischemic brain injury, calcification of Smooth Muscle (SM) cells, Skeletal Muscle (SK) degeneration, chronic and acute renal injury, Pancreatic degeneration, and Acute respiratory distress/injury. The mechanism of affect is shown by positive regulation in the blue arrow and negative regulation in the red line.](fcell-08-00149-g001){#F1}

Clinical Use of Msc-Ev {#S3}
======================

There are few published studies demonstrating the clinical effectiveness of MSC-EV. In one study, hBMMSC-EV were tested in patients suffering from steroid refractory graft-versus-host disease ([@B41]). Outcomes of the study revealed significant improvements in graft-versus-host disease symptoms. In another study, administration of hUCMSC-EV resulted in overall improvement in kidney function in grade III-IV chronic kidney disease patients ([@B59]). [@B59] conducted a clinical trial to assess the effects of hUCMSC-EV on pancreatic islet beta cell mass in Type-1 diabetic patients (trial NCT02138331). Results of this clinical trial are not yet published. However, a supporting preclinical study suggested that intravenous administration of hUCMSC led to reduced blood sugar level as the main paracrine approach of MSCs and partially reversed insulin resistance in Type 2 diabetes mellitus indirectly to accelerate glucose metabolism ([@B94]). Also, with other MSC, it was shown that hBMMSCs led to the suppression of autoimmunity and the regeneration of islet beta cells, therefore preventing the onset of Type-1 diabetes ([@B23]; [@B100]). Moreover, there are other ongoing trials conducted to determine the safety and efficacy of human MSC-EV -- one led by Zhang et al. (NCT03437759) using hUCMSCs to promote healing of large and refractory macular holes and another by Zali et al. (NCT03384433) using miR-124-loaded exosomes in patients with acute ischemic stroke. While many clinical studies are in the recruitment and active phases, much of these terminate without producing a significant publication.

Challenges in Clinical Applications {#S4}
===================================

Despite the therapeutic success of MSC-EV in preclinical studies, use of these EV in clinical settings will require resolution of several critical issues such as (i) large-scale production and isolation methods, (ii) methods for rapid and accurate quantification and characterization of EV, (iii) precise content characterization of the cargo, (iv) pharmacokinetics, targeting and transfer mechanisms of EV to the target sites, and (v) safety profiles to determine the optimal clinical dosage and possible toxicities upon repeated administration.

Large-Scale Production of MSC-EV {#S4.SS1}
--------------------------------

Traditional methods for maintenance and expansion of cells rely on a two-dimensional culture technique. Long-term passaging to produce sustainable quantities of EV may cause the cells to lose clonal and differentiation capacity ([@B52]). Therefore, there is an urgent need for development of methods for reliable expansion of MSCs to mass produce EV for clinical use. Current methods of expansion of MSCs are labor-intensive and involve several procedures. The methods available for MSCs culture expansions are: (i) traditional tissue culture techniques in flasks ([@B62]; [@B66]) or (ii) use of three-dimensional culturing bioreactors made up of polysulphone hollow fibers with semi-permeable membranes that greatly increase the surface area, as described by [@B54] and ([@B52]). Unfortunately, the existing methods for EV production have low yields and are not scalable, impeding the progress of preclinical and clinical use of EV as therapeutics ([@B87]). Large-scale EV production employs the use of large or multi-layer culture flasks, fixed-bed bioreactors, in-stirred tank bioreactors, or continuous production in perfusion reactors ([@B18]). Most of these methods aim to increase the EV production through maximizing the culture surface area as compared to the conventional planar cell culture in flasks ([@B88]). Supporting this notion, a recent study showed that cultivation of hUCMSCs in scalable microcarrier-based three-dimensional cultures resulted in twenty-fold greater yield of EV than two-dimensional cultures ([@B29]).

Several technical factors when using cell culture supernatants for EV extraction need to be standardized to ensure batch-to-batch reproducibility and lot-consistent EV-production ([@B89]). Many factors can affect the quality and quantity of the EV produced from the MSCs, such as cellular confluence, early versus later passage of cells, oxygen concentration, cytokines, heparin, and serum content of the medium ([@B47]). For instance, studies show that fetal bovine serum (FBS), a nutrient for growing cells in culture, has RNA-containing EV that can affect the cell culture behavior, highlighting the importance of developing a protocol where EV are generated without such interferences ([@B74]). Also, serum-free cultures are shown to alter EV quantity and protein composition ([@B49]). Addressing this issue, [@B68] developed a Good Manufacturing Practice (GMP)-grade standard protocol where they showed that hBMMSCs cultured in EV-depleted medium with reduced pooled human platelet lysate (a serum-free medium) (i) retained their morphology, phenotype, viability and differential potential, (ii) strongly affected hBMMSC proliferation and differentiation capacities, (iii) were enriched in hBMMSC-EV, and (iv) showed unchanged EV-RNA profiles that originated from hBMMSCs ([@B68]). This study offers an option for GMP-compliant large-scale production of MSCs and MSC-EV. Apart from manipulating the culture conditions, manipulating the EV-biogenesis biology may also improve the yield of EV ([@B69]).

Effective and Scalable EV Isolation Methods From MSCs Culture Medium {#S4.SS2}
--------------------------------------------------------------------

Besides large-scale manufacturing of EV, scalable EV isolation techniques are lacking, making clinical translation of EV therapeutics difficult. Currently, there are various methods available for EV isolation ([@B51]; [@B48]); however, there is no state-of-the-art technology to isolate EV in large quantities for clinical use. In research, there are five major isolation methods: (i) differential centrifugation, (ii) density gradient ultracentrifugation, (iii) size-exclusion chromatography (SEC), (iv) precipitation, and (v) immune-based capture method ([@B18]). Interestingly, many research groups ([@B64]; [@B8]; [@B56]) have demonstrated that EV isolated from stem cell culture by ultrafiltration followed by SEC results in higher yield while preserving EV biophysical and functional properties ([@B57]).

The popularity of SEC in both therapeutics and biomarker discovery for disease diagnosis was explored by [@B75] to demonstrate the superiority of SEC qEV (Izon Science) over affinity-based EV isolation method (using exoEasy kit, Qiagen) from human plasma. Intriguingly, SEC alone is unable to separate plasma EV from lipoproteins unless combined with density gradient isolation ([@B35]).

Biodistribution and Targeting of MSC-EV to Target Tissues {#S4.SS3}
---------------------------------------------------------

To investigate MSC-EV as a therapeutic tool, it is critical to consider their biodistribution and targeting mechanisms *in vivo*. One method of studying different tissue targets in living animals is optical imaging (OI). This non-invasive method can visualize labeled cells *in vivo* using near-infrared (NIR) dyes that maximize depth of tissue penetration and reduce background ([@B71]; [@B10]; [@B79]; [@B27]; [@B86]). In a mouse model of acute kidney injury (AKI), [@B27] used two methods for the labeling of MSC-EV: direct labeling of purified EV and generation of labeled EV from MSCs pre-incubated with NIR dye. They found that EV were detectable in whole-body images and dissected kidneys using OI, and EV that were directly labeled with NIR dye showed higher and brighter fluorescence compared to the labeled EV produced by MSCs. They also found that MSC-EV accumulated in the kidneys of their AKI mice but not in controls. MSCs are recruited to sites of injury via receptor-mediated interactions ([@B31]), therefore MSC-EV, which have the same membrane receptors of MSCs, may be recruited to the site of injury via the same mechanism ([@B27]).

Researchers have used different dyes to track the biodistribution of EV after their administration. [@B86] used DiD lipid dye-labeled MSC-EV to assess their distribution in mice under various conditions. The DiD-labeled MSC-EV distributed maximally in the liver and spleen, lesser in the bone marrow of the spine, femur, and tibia, and were undetectable in the lung, heart, and kidney ([@B86]). PKH-26A, a lipophilic dye that integrates into cell membranes, is commonly used to label MSC-EV ([@B13]; [@B34]; [@B43]). [@B13] evaluated the effects of rat adipose-derived MSC-EV (rAMSC-EV) on sciatic nerve regeneration and neurite growth. rAMSC-EV enhanced the regeneration of the sciatic nerve *in vivo* after injury and neurite growth *in vitro*. They also characterized neural growth factor transcripts in rAMSC-EV ([@B13]). Another study from [@B83] used DIO to label MSC-EV in a rat carotid artery balloon injury model. They found that MSC-EV can transfer miR−125b to vascular smooth muscle cells, which can attenuate neointimal formation and could be a therapeutic target of vascular diseases ([@B83]). There are also several reports of labeling MSC-EV with different labeling agents such as DiI (1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindocarbocyanine Perchlorate), Alexa fluor 488, and gadolinium for locating the biodistribution of EV ([@B1]; [@B16]; [@B19]).

Furthermore, a study from [@B58] investigated the biodistribution, therapeutic efficacy, and mode of action of MSC-EV in a preclinical rat model of stroke. This study used PKH26 or 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) to label EV for *in vivo* tracking. EV were identified and counted using flow cytometry, and Nanosight nanoparticle tracking analysis was used to measure size and morphology ([@B58]). They found that MSC-EV migrated to the infarcted brain. While MSC-EV accumulated in the infarcted brain in a dose-dependent manner, injected MSCs aggregated in the lung and liver with increasing doses, again highlighting that MSCs rarely make it to target tissues ([@B25]).

The mechanism of therapeutic action of EV is still unclear. EV-cargo can include membrane proteins, cytoplasmic proteins, mRNAs, and microRNAs, which can all be delivered to recipient cells. It is speculated that the therapeutic effect of EV comes through the transfer of miRNAs to diseased and injured cells ([@B28]). Studies have shown that miRNAs in MSC-EV influence physiology and pathophysiology of microenvironments ([@B91]; [@B58]). Additionally, miRNAs from MSC-EV have been shown to influence cardiac regeneration and protection ([@B65]). Strategies for loading and modifying the EV-cargo exist; electroporation, freeze-thaw cycles, saponin-mediated loading, and hypotonic dialysis have all been studied for use in exogenously loading EV ([@B42]; [@B53]). EV cargo may also influence EV migration. It is speculated that MSC-EV express chemokine receptors that facilitate targeting to injured regions ([@B38]; [@B58]). Decoration of the EV surface with phosphatidylserine-binding and HER2-targeting proteins has been shown to increase EV delivery to HER2-expressing cells ([@B84]). Other studies demonstrate the feasibility of this decorating method of targeting EV to specific tissues ([@B2]; [@B40]; [@B3]), so perhaps these strategies may be applied to MSC-EV as well. Though the exact mechanism is not known, it is speculated that MSC-EV function similarly to MSCs. MSCs exert therapeutic effects through the secretion of factors that reduce cellular injury and promote repair, and MSC-EV may function as communication vehicles employed by MSCs to signal support from the tissue microenvironment ([@B36]; [@B96]).

Safety Profile {#S4.SS4}
--------------

With any therapeutic treatment, a safety profile must be established. While EV-based treatment is in its clinical infancy we know that many of the harmful effects of cell therapies are absent in EV-based treatments. The main apprehension for using stem cell therapy is the differentiation of the transplanted MSCs and the potential of MSCs to suppress anti-tumor immune responses and act as a progenitor for blood vessels, which potentially promote tumor growth and metastasis ([@B14]). Further, MSCs are hindered by their tumorigenicity, immunogenicity, and genomic mutability ([@B30]; [@B39]; [@B99]). Fortunately, MSC-EV are not affected by the above-mentioned limitations. A few clinical trials have been performed utilizing EV (not derived from MSCs) and these studies have established good safety profiles for treatments with ascite- and dendrite-derived EV ([@B70]). EV inherently lack the features to cause the above-mentioned issues which, for many researchers, mark them as attractive candidates for use as therapeutic agents. Future clinical research will likely see a huge upswing in the utilization of stem cell-derived EV in place of its progenitor cell sources.

Conclusion {#S5}
==========

The future of MSCs has long been anticipated, and there is no doubt with the discoveries coming forth and the exponentially increasing amount of clinical trials that they will provide therapies for a myriad of heretofore untreated maladies. However, it is possible that the future of MSCs will be dominated by MSC-EV. The EV's ability to operate similarly to MSCs while not possessing many of the drawbacks extant in cell-based therapies provide them a unique niche in therapeutics.

The future of MSC-EV is dependent on the large-scale culturing of MSCs. This key step in manufacturing will open the door for them to be considered a successful therapeutic option. Standardizing treated culturing of MSCs will be a necessary future development; these EV will be treated in hypoxic conditions and likely treated with miRNA applications. Both of these conditions will significantly increase MSC growth while also increasing release of EV. Additionally, increasing the proliferation of EV isolation is another issue. For therapeutic purposes, many isolation methods can be ignored for either damage, interference, or low yield of EV. There are increasing developments being made in the field of EV isolation and characterization. SEC, with its ability to provide unaltered and selective EV, has replaced standard methodologies like immunoprecipitation and density-gradient centrifugation. Despite EV being touted for the lack of a toxic profile, the ability to include a range of specifically sized EV is an important focus in the field of EV research, especially in therapeutics. SEC allows for the more precise extraction of EV, which can ensure specific and more efficient treatments.

The biodistribution and targeting of MSC-EV is a simpler matter, despite being poorly understood. These EV act as key messengers between MSCs and damaged tissues. While MSCs might aggregate in unintended organs and tissues, their secreted EV target damaged tissues. To increase our understanding of potentially confounding effects of MSC-EV, a greater understanding of their targeting and biodistribution is necessary. Presently, clinical and preclinical trials have not reported unintended targeted effects. With few complications and a range of benefits, MSC-EV are increasingly researched despite issues with large-scale production.
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